Dr. Girindra Raval, MD
Claim this profileAugusta University Medical Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
7 reported clinical trials
11 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage II
Stage III
Stage I
2Lung Cancer
Stage II
Stage I
Stage III
Affiliated Hospitals
Clinical Trials Girindra Raval, MD is currently running
Monalizumab or Oleclumab with Durvalumab and Radiation
for Lung Cancer
This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.
Recruiting1 award Phase 110 criteria
CAB-ROR2-ADC + PD-1 Inhibitor
for Breast Cancer
This trial is testing a new targeted cancer treatment called CAB-ROR2-ADC in patients with advanced solid tumors. The drug seeks out cancer cells with a specific marker and delivers a potent treatment directly to them.
Recruiting1 award Phase 1 & 29 criteria
More about Girindra Raval, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Girindra Raval, MD has experience with
- Atezolizumab
- PD-1 Inhibitor
- Hypofractionated Radiation Therapy
- CAB-AXL-ADC
- Talazoparib
- Stereotactic Body Radiation Therapy
Breakdown of trials Girindra Raval, MD has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Small Cell Lung Cancer
Small Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Girindra Raval, MD specialize in?
Girindra Raval, MD focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Girindra Raval, MD currently recruiting for clinical trials?
Yes, Girindra Raval, MD is currently recruiting for 4 clinical trials in Augusta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Girindra Raval, MD has studied deeply?
Yes, Girindra Raval, MD has studied treatments such as Atezolizumab, PD-1 inhibitor, Hypofractionated Radiation Therapy.
What is the best way to schedule an appointment with Girindra Raval, MD?
Apply for one of the trials that Girindra Raval, MD is conducting.
What is the office address of Girindra Raval, MD?
The office of Girindra Raval, MD is located at: Augusta University Medical Center, Augusta, Georgia 30912 United States. This is the address for their practice at the Augusta University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.